Canadian (TSX) Healthcare Sector Analysis

Sector Valuation and Performance

Has the Canadian Healthcare Sector valuation changed over the past few years?

Date	Market Cap	Revenue	Earnings	PE	Absolute PE	PS
Tue, 28 Jul 2026	CA$33.8b	CA$17.2b	-CA$1,952,178,062.70	33.3x	-17.3x	2x
Thu, 25 Jun 2026	CA$33.4b	CA$17.3b	-CA$1,956,940,932.16	17.7x	-17x	1.9x
Sat, 23 May 2026	CA$35.7b	CA$18.7b	-CA$2,110,741,481.73	21.8x	-16.9x	1.9x
Mon, 20 Apr 2026	CA$34.1b	CA$17.4b	-CA$1,902,227,493.03	25.7x	-17.9x	2x
Wed, 18 Mar 2026	CA$32.4b	CA$17.1b	-CA$2,003,021,539.33	19.8x	-16.2x	1.9x
Fri, 13 Feb 2026	CA$32.4b	CA$17.5b	-CA$2,140,107,063.54	20.4x	-15.1x	1.8x
Sun, 11 Jan 2026	CA$36.3b	CA$19.3b	-CA$2,234,318,057.72	22.7x	-16.2x	1.9x
Tue, 09 Dec 2025	CA$33.0b	CA$19.2b	-CA$2,177,690,520.27	20.7x	-15.1x	1.7x
Thu, 06 Nov 2025	CA$33.6b	CA$18.9b	-CA$2,402,456,611.88	37.9x	-14x	1.8x
Sat, 04 Oct 2025	CA$38.2b	CA$19.4b	-CA$2,311,886,247.31	42.5x	-16.5x	2x
Mon, 01 Sep 2025	CA$36.2b	CA$20.0b	-CA$2,786,491,292.97	44.9x	-13x	1.8x
Wed, 30 Jul 2025	CA$29.3b	CA$19.6b	-CA$2,743,275,639.92	20x	-10.7x	1.5x
Fri, 27 Jun 2025	CA$27.0b	CA$19.5b	-CA$2,790,105,106.70	20.9x	-9.7x	1.4x
Sun, 25 May 2025	CA$40.8b	CA$19.6b	-CA$2,682,158,941.30	20.8x	-15.2x	2.1x
Tue, 22 Apr 2025	CA$25.3b	CA$19.6b	-CA$2,814,946,224.45	25.6x	-9x	1.3x
Thu, 20 Mar 2025	CA$26.3b	CA$19.9b	-CA$2,891,907,912.98	20.4x	-9.1x	1.3x
Sat, 15 Feb 2025	CA$28.9b	CA$19.7b	-CA$2,496,625,361.39	27.4x	-11.6x	1.5x
Mon, 13 Jan 2025	CA$28.1b	CA$19.8b	-CA$2,731,688,290.95	28.7x	-10.3x	1.4x
Wed, 11 Dec 2024	CA$29.8b	CA$19.8b	-CA$2,895,776,227.88	24.2x	-10.3x	1.5x
Fri, 08 Nov 2024	CA$30.5b	CA$19.5b	-CA$2,989,396,191.97	20.2x	-10.2x	1.6x
Sun, 06 Oct 2024	CA$32.7b	CA$19.3b	-CA$2,951,499,763.62	21.3x	-11.1x	1.7x
Tue, 03 Sep 2024	CA$31.2b	CA$19.2b	-CA$2,960,388,276.77	21.5x	-10.6x	1.6x
Thu, 01 Aug 2024	CA$34.0b	CA$19.2b	-CA$3,668,508,186.25	20.3x	-9.3x	1.8x
Sat, 29 Jun 2024	CA$34.2b	CA$19.3b	-CA$3,791,582,883.16	20.6x	-9x	1.8x
Mon, 27 May 2024	CA$34.0b	CA$19.5b	-CA$4,062,639,973.01	15x	-8.4x	1.7x
Wed, 24 Apr 2024	CA$34.8b	CA$19.3b	-CA$4,048,089,891.00	13.7x	-8.6x	1.8x
Fri, 22 Mar 2024	CA$34.6b	CA$19.3b	-CA$4,048,674,949.60	12.6x	-8.6x	1.8x
Sun, 18 Feb 2024	CA$34.1b	CA$19.3b	-CA$5,204,326,536.44	15.4x	-6.6x	1.8x
Tue, 16 Jan 2024	CA$37.1b	CA$20.1b	-CA$7,674,754,170.00	10.4x	-4.8x	1.8x
Thu, 14 Dec 2023	CA$31.9b	CA$20.1b	-CA$7,711,376,481.00	13.1x	-4.1x	1.6x
Sat, 11 Nov 2023	CA$31.6b	CA$20.1b	-CA$7,766,295,492.00	17.2x	-4.1x	1.6x
Mon, 09 Oct 2023	CA$33.6b	CA$20.0b	-CA$8,389,630,679.00	16.9x	-4x	1.7x
Wed, 06 Sep 2023	CA$35.7b	CA$20.6b	-CA$8,953,050,739.00	18x	-4x	1.7x
Fri, 04 Aug 2023	CA$30.9b	CA$20.7b	-CA$10,825,716,461.00	19.5x	-2.9x	1.5x

Current Industry PE

Investors are optimistic on the Canadian Healthcare industry, and appear confident in long term growth rates.

The 3-year average PS ratio of 1.7x is lower than the industry's current PS ratio of 2.0x.

Past Earnings Growth

The earnings for companies in the Healthcare industry have improved over the last three years.
Meanwhile revenues for these companies have declined 5.9% per year.
This means that less sales are being generated overall, but since the cost of doing business is lower, losses have been shrinking.

Industry Trends

Which industries have driven the changes within the Canadian Healthcare sector?


CA Market	1.56%
Healthcare	-0.091%
Medical Equipment	7.22%
Life Sciences	1.91%
Healthcare Services	0.90%
Biotech	0.14%
Healthtech	-1.43%
Pharma	-1.44%

Industry PE

Investors are most optimistic about the Healthcare Services industry which is trading above its 3-year average PE ratio of 14.5x.

Analysts are expecting annual earnings growth of 54.4%, which is higher than its past year's earnings decline of 11.9% per year.

Forecasted Growth

Analysts are most optimistic on the Healthtech industry, expecting annual earnings growth of 92% over the next 5 years.
However this is lower than its past earnings growth rate of 157% per year.

In contrast, the Biotech industry is expected to see its earnings decline by 12% per year over the next few years.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

Company	Last Price	7D	1Y	Valuation
CSH.UN Chartwell Retirement Residences	CA$23.19	2.2% +CA$162.1m	34.4%	PE1778.7x
CRON Cronos Group	CA$4.06	2.8% +CA$41.1m	43.5%	PS6.7x
MSCL Satellos Bioscience	CA$13.30	13.5% +CA$32.9m	105.2%	PB2.8x
PRN Profound Medical	CA$10.44	8.8% +CA$30.5m	33.8%	PS14.3x
ZEN Zentek	CA$0.81	26.6% +CA$21.5m	-39.1%	PS617.7x

Profound Medical Corp. Presents New Data from Captain Trial Demonstrating Tulsa Procedure Superior Penile Length Preservation Compared to Robotic Radical Prostatectomy

Profound Medical Corp. announced new data from the Level 1 post-market CAPTAIN randomized controlled trial comparing the TULSA Procedure with robotic radical prostatectomy in men with organ-confined, intermediate-risk, Gleason Score 7 (Grade Group 2 and 3) prostate cancer. At 1 month following the TULSA Procedure, there was no median change in penile length, compared with a median 0.65 cm reduction in penile length after robotic radical prostatectomy. No median change in penile length at 1 month after whole-gland TULSA, compared with a median 0.65 cm reduction in penile length after robotic radical prostatectomy. A statistically significant between-arm difference in change in penile length estimated from a mixed-effects model (0.42 cm; p. CAPTAIN (A Comparison of TULSA Procedure vs. Radical Prostatectomy in Participants with Localized Prostate Cancer) is a prospective, multi-center randomized controlled trial aimed at comparing the safety and efficacy of the TULSA Procedure (performed with the TULSA-PRO system) with robotic radical prostatectomy in men with organ-confined, intermediate-risk, Gleason Score 7 (Grade Group 2 and 3) prostate cancer. CAPTAIN exceeded its enrollment target, treating 211 patients, instead of the initially planned 201 patients, by August 2025 at 20 sites in the United States, two in Canada and one in Europe. The goal of CAPTAIN is to demonstrate that the efficacy of the TULSA procedure is not inferior to robotic radical prostatectomy, while demonstrating superior quality of life outcomes. The primary safety endpoint is the proportion of patients who preserve both erectile potency and urinary continence at one year after treatment. The primary efficacy endpoint is the proportion of patients who are free from any additional treatment for prostate cancer, free of metastases or prostate cancer related death by three years after treatment. Secondary endpoints include comparison of rates of complications, cost effectiveness, as well as histologic and biochemical failure. TULSA-PRO enables MRI-guided, incision-free prostate ablation. Physicians use the TULSA Procedure to see, ablate, and confirm therapy in real time, supporting personalized treatment strategies across the continuum of prostate care—from whole-gland to subtotal, hemi, multifocal, and focal treatment. This approach enables individualized care using prostate tissue ablation, while minimizing the potential of the side effects that are typically associated with surgery or radiation, such as urinary incontinence and/or erectile dysfunction. Profound also commercializes Sonalleve, an MRI-guided therapy that provides a non-surgical treatment option for pain palliation of bone metastases, desmoid tumors, and osteoid osteoma, as well as for common gynecologic conditions including uterine fibroids and adenomyosis. Sonalleve delivers targeted therapy with no incisions, no blood loss during the procedure, no overnight hospital stay, and faster recovery — and, in gynecologic applications, enables uterine-sparing treatment that may help preserve fertility. Profound is also exploring additional clinical applications for Sonalleve, including non-invasive ablation of abdominal cancers and hyperthermia-based cancer therapies. Profound Medical’s technologies are approved across major global markets. TULSA-PRO is cleared by the FDA in the United States for transurethral ultrasound ablation of prostate tissue. In addition, TULSA-PRO is cleared for use in various jurisdictions including Europe, Canada, Saudi Arabia, India, Australia/New Zealand, and the UAE. Sonalleve is approved by the FDA as HDE in the United States for the treatment of osteoid osteomas in the extremities. Sonalleve is also cleared or approved in the Europe, Canada, China, and Saudi Arabia.

Canadian (TSX) Healthcare Sector Analysis

Sector Valuation and Performance

Industry Trends

Top Stock Gainers and Losers

Latest News

Price target decreased by 8.1% to CA$5.64

Now 40% overvalued after recent price rise

Grown Rogue International Inc. to Report Q2, 2026 Results on Aug 04, 2026

Chartwell Announces Property Sales in Ontario and New Projects in Quebec, Alberta and BC

Profound Medical Corp. Presents New Data from Captain Trial Demonstrating Tulsa Procedure Superior Penile Length Preservation Compared to Robotic Radical Prostatectomy

CURA: International Supply Deals And Spain Approval Will Support Future Upside Potential

Investor sentiment deteriorates as stock falls 21%

Dividend of CA$0.044 announced

Independent Director recently bought CA$117k worth of stock

Apotex Health Achieves Investment Grade Rating and Updates Credit Terms to Lower Costs

Cronos Group Inc. to Report Q2, 2026 Results on Aug 06, 2026

WELL Health Technologies Corp. announced that it has received CAD 150 million in funding

VRNO: Florida Expansion And DEA Rescheduling Pathway Will Drive Future Upside

Cresco Labs Inc. to Report Q2, 2026 Results on Aug 06, 2026

We're Not Very Worried About Bright Minds Biosciences' (CSE:DRUG) Cash Burn Rate

Full year 2026 earnings released: CA$0.09 loss per share (vs CA$0.097 loss in FY 2025)